State Street Corp boosted its position in Cryoport, Inc. (NASDAQ:CYRX – Free Report) by 2.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,003,080 shares of the company’s stock after acquiring an additional 27,438 shares during the period. State Street Corp owned 2.03% of Cryoport worth $8,135,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company boosted its stake in shares of Cryoport by 9.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 17,683 shares of the company’s stock valued at $122,000 after purchasing an additional 1,534 shares during the last quarter. Rhumbline Advisers lifted its holdings in Cryoport by 3.4% in the second quarter. Rhumbline Advisers now owns 64,158 shares of the company’s stock valued at $443,000 after buying an additional 2,086 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Cryoport by 0.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 387,714 shares of the company’s stock valued at $3,144,000 after acquiring an additional 2,226 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Cryoport during the 3rd quarter worth $82,000. Finally, Quest Partners LLC grew its holdings in Cryoport by 1,083,000.0% during the 2nd quarter. Quest Partners LLC now owns 10,831 shares of the company’s stock worth $75,000 after acquiring an additional 10,830 shares during the period. 92.90% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several research analysts have recently issued reports on the company. Roth Mkm reduced their price target on Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, November 8th. Guggenheim assumed coverage on Cryoport in a report on Thursday, December 19th. They set a “buy” rating and a $11.00 target price on the stock. Finally, UBS Group boosted their target price on Cryoport from $7.00 to $9.00 and gave the stock a “neutral” rating in a research report on Friday, October 18th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $12.29.
Insider Activity
In related news, Director Ramkumar Mandalam sold 7,369 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $7.46, for a total transaction of $54,972.74. Following the completion of the transaction, the director now directly owns 59,497 shares of the company’s stock, valued at approximately $443,847.62. This represents a 11.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Jerrell Shelton sold 50,000 shares of the company’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $6.51, for a total value of $325,500.00. Following the sale, the chief executive officer now owns 731,897 shares in the company, valued at approximately $4,764,649.47. This represents a 6.39 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 109,869 shares of company stock worth $735,673 over the last ninety days. Insiders own 10.10% of the company’s stock.
Cryoport Stock Down 3.5 %
Shares of Cryoport stock opened at $7.80 on Friday. Cryoport, Inc. has a 52-week low of $5.32 and a 52-week high of $20.10. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. The business’s 50 day simple moving average is $7.44 and its 200 day simple moving average is $7.95. The firm has a market cap of $385.56 million, a PE ratio of -2.31 and a beta of 1.62.
Cryoport Company Profile
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
Read More
- Five stocks we like better than Cryoport
- Top Biotech Stocks: Exploring Innovation Opportunities
- S&P 500 ETFs: Expense Ratios That Can Boost Your Long-Term Gains
- How to Use High Beta Stocks to Maximize Your Investing Profits
- How AI Implementation Could Help MongoDB Roar Back in 2025
- What is a Death Cross in Stocks?
- Hedge Funds Boost Oil Positions: Is a Major Rally on the Horizon?
Want to see what other hedge funds are holding CYRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cryoport, Inc. (NASDAQ:CYRX – Free Report).
Receive News & Ratings for Cryoport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with MarketBeat.com's FREE daily email newsletter.